# Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

> **NCT07315854** · PHASE2 · RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Gastric Cancer (GC)
- Gastroesophageal Junction Cancer
- Advanced Gastric Cancer
- Metastatic Gastric Cancer

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)
- **DRUG:** SOX Chemotherapy

## Key facts

- **NCT ID:** NCT07315854
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07315854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07315854, "Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07315854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*